At Benchling, we work with scientists across disciplines throughout academia and industry. In the second of our series of customer videos, we share the story of our partnership with Obsidian Therapeutics, a company that is developing next-generation cell and gene therapies with pharmacologic operating systems. We spoke with Vipin Suri, Vice President of Discovery, about Obsidian’s journey with Benchling, which started back in 2016. In this video we discuss collaboration, reducing busywork for scientists and unlocking pivotal R&D answers.
Visit our Customer Stories page to learn more about how companies use Benchling to accelerate their biologics R&D.